Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy – Final report
A. Jürgens, H. Pels, A. Glasmacher, H. Schulz, K. Fliessbach, M. Linnebank, M. Vogt-Schaden, H. Reichmann, I.G.H. Schmidt-Wolf, U. Schlegel · Aktuelle Neurologie · 2006 · Heft 09
Bibliografische Angaben
Zusammenfassung
Objectives: To evaluate response rate, response duration, overall survival, and toxicity in primary central nervous system lymphoma (PCNSL) after systemic and intraventricular chemotherapy with deferred radiotherapy. Patients and Methods: From 09/1995 to 12/2002, 88 patients with PCNSL (median age 62 years) were enrolled in a pilot/phase II study evaluating chemotherapy without radiotherapy. A high-dose methotrexate (MTX) (cycles 1,2,4,5) and cytarabine (ara-C) (cycles 3,6) based systemic therapy (including dexamethasone, vinca-alkaloids, ifosfamide and cyclophosphamide) was combined with intraventricular MTX, p…
